Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Background: TRC102 inhibits base excision repair by binding abasic sites and preventing AP endonuclease processing; it potentiates the activity of alkylating agents, including temozolomide, in murine models. In published xenograft studies, TRC102 enhanced the antitumor effect of temozolomide regardl...

Descripción completa

Detalles Bibliográficos
Autores principales: Coyne, Geraldine O'Sullivan, Kummar, Shivaani, Meehan, Robert S., Do, Khanh, Collins, Jerry M., Anderson, Larry, Ishii, Kazusa, Takebe, Naoko, Zlott, Jennifer, Juwara, Lamin, Piekarz, Richard, Streicher, Howard, Sharon, Elad, Rubinstein, Larry, Voth, Andrea Regier, Lozier, Jay, Dull, Angie B., Wilsker, Deborah, Hinoue, Toshinori, Laird, Peter W., Ferry-Galow, Katherine V., Kinders, Robert J., Parchment, Ralph E., Doroshow, James H., Chen, Alice P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646836/
https://www.ncbi.nlm.nih.gov/pubmed/33216844
http://dx.doi.org/10.18632/oncotarget.27784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646836/
https://www.ncbi.nlm.nih.gov/pubmed/33216844
http://dx.doi.org/10.18632/oncotarget.27784

Ejemplares similares